Hemophilia B is a congenital hemorrhagic disorder linked to the X chromosome caused by a deficiency in the coagulation factor procoagulant activity IX. And patients affected by this disease suffer spontaneous or traumatic bleeding on a recurring basis, both at the tissue level and at the joints, which can cause severe degenerative arthropathies. Its most serious complications are hemorrhages at the level of the central nervous system, which can cause death.
The medications, financed from March 1, are aimed at preventing and treating these hemorrhages and having a longer half-life patients will go from having a need for administrations every 3 or 4 days instead of every 10 or 14. This It will have a direct impact on your quality of life and that of your environment. And, with this, the adherence to the treatment is also improved.
This agreement, which was adopted unanimously by the Interministerial Commission of Drug Prices, of which all the autonomous communities are part, comes after a search for joint solutions among professionals, patients through the Spanish Federation of Hemophilia, the Health administrations and titular laboratories.
In this way, equitable access to these therapies that since 2016 were authorized in Europe and not funded in Spain is guaranteed.